Image
Online Series

Pharmacy PrEP Education

A “How To” Series Spanning Policy to Practice

PrEP Pharmacy Monograph and State-Supplements

Providing PEP/PrEP in the Pharmacy Setting: A Comprehensive User Guide

Are you seeking specific insights and suggestions as you prepare to implement postexposure prophylaxis (PEP) and preexposure prophylaxis (PrEP) in your pharmacy practice? This activity qualifies participants for 2.0 CPE credits to fulfill State Board of Pharmacy training requirements

Calling all pharmacists from: Nevada, Oregon, and Virginia!

Your Board of Pharmacy has recently expanded your scope of practice to include prescribing and dispensing of PrEP and PEP. Learn the details specific to your state with these short primers:

 

CLINICAL PRACTICE GUIDELINES

Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update. A clinical practice guideline.

US Public Health Service. Centers for Disease Control and Prevention; 2021.

Sexually transmitted infections treatment guidelines, 2021.

Centers for Disease Control and Prevention. Last reviewed July 2021.

Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016.

CDC Stacks. Centers for Disease Control and Prevention; last updated May 2018.

The Fenway Guide to Lesbian, Gay, Bisexual, and Transgender Health.

Makadon HJ, et al, American College of Physicians (ACP), eds. 2nd ed. Boston, MA: Fenway Health; 2015.

Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society—USA Panel.

Saag MS, et al. JAMA. 2020;324(16):1651-1669.

ASHP [American Society of Health-System Pharmacists] guidelines on pharmacist involvement in HIV care.

Schafer JJ, et al. Am J Health Syst Pharm. 2016;73(7):468-494.

Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.

US Department of Health and Human Services; last updated January 2022.

PROFESSIONAL ORGANIZATIONS & RESOURCES

American Academy of HIV Medicine.

A guide to taking a sexual history.

Centers for Disease Control and Prevention. 2022.

Basic statistics.

Centers for Disease Control and Prevention; updated April 2022.

HIV testing.

Centers for Disease Control and Prevention; June 2022.

HIV testing in retail pharmacies (training for pharmacists and pharmacy staff).

Centers for Disease Control and Prevention; Updated 2022.

Taking Routine Histories of Sexual Health: A System-Wide Approach for Health Centers.

National LGBTQIA+ Health Education Center. 2016.

Ending the HIV epidemic: Ready, Set, PrEP!

US Department of Health and Human Services.

Please PrEP Me

Both professional and patient resources as well as a state-by-state list of PrEP resources in all 50 states.

Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update. Clinical providers’ supplement.

US Public Health Service. Centers for Disease Control and Prevention; 2021.

National Clinician Consultation Center.

University of California, San Francisco; 2020.

HIV drug interactions.

University of Liverpool (website); updated July 2022.

Sexual History Taking Toolkit.

TargetHIV. 2022.

PATIENT RESOURCES

HIV basics.

Centers for Disease Control and Prevention; April 2021.

Prevention for women. Resources on HIV prevention for U.S. women.

HIVE online; 2019.

HIV resources.

National Institutes of Health; September 2020.

Positively Aware.

Positively Aware, created by TPAN (Test Positive Aware Network), is a source of HIV-treatment news for consumers, as well as an educational tool for HIV caregivers. The site features PrEP resources, including videos for men who have sex with men and transgender people.

UCSF transgender care.

University of California, San Francisco; 2019.

Suggested Readings

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Baeten JM, et al. N Engl J Med. 2012;367(5):399-410.

Stigma, medical mistrust, and perceived racism may affect PrEP awareness and uptake in black compared to white gay and bisexual men in Jackson, Mississippi and Boston, Massachusetts.

Cahill S, et al. AIDS Care. 2017;29(11):1351-1358.

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

Choopanya K, et al. Lancet. 2013;381(9883):2083-2090.

Assessing the efficacy and feasibility of a retail pharmacy-based HIV testing program. 

Collins BC, et al. 24th Conference on Retroviruses and Opportunistic Infections (CROI) 2017; February 13-17, 2017; Seattle, WA. Abstract 962.

Community pharmacy delivered PrEP to STOP HIV transmission: an opportunity NOT to miss!

Lopez MI, et al. J Am Pharm Assoc (2003). 2020;60(4):e18-e24.

Why don't patients take their drugs? The role of communication, context and culture in patient adherence and the work of the pharmacist in HIV/AIDS.

Penn C, et al. Patient Educ Couns. 2011;83(3):310-318.

4 findings from a successful HIV PrEP program.

Ross M. Pharm Times. 2016-01-07;15:30:00.

Truvada: emtricitabine/tenofovir disoproxil.

European Medicines Agency (EMA). 2021.

Emtricitabine/tenofovir alafenamide.

HIV.gov. Drug database.

Emtricitabine/tenofovir disoproxil fumarate.

HIV.gov. Drug database.  

Cabotegravir.

HIV.gov. Drug database.

Being PrEPared—preexposure prophylaxis and HIV disparities.

Goldstein RH, et al. N Engl J Med. 2018;379(14):1293-1295.

Lifetime risk of a diagnosis of HIV infection in the United States.

Hess KL, et al. Ann Epidemiol. 2017;27(4):238-243.

Cabotegravir for HIV prevention in cisgender men and transgender women.

Landovitz RJ, et al. N Engl J Med. 2021;385(7):595-608.

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

Mayer KH, et al. Lancet. 2020;396(10246):239-254.

Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care.

Tung EL, et al. Sex Health. 2018;15(6):556-561.

HIV testing in community pharmacies and retail clinics: a model to expand access to screening for HIV infection.

Weidle PJ, et al. J Am Pharm Assoc. 2014; 54(5):486-492.

Activity
Optimizing PrEP Access Through Advocacy

Pharmacy PrEP Education: A “How To” Series Spanning Policy to Practice

Activity
Providing PEP/PrEP in the Pharmacy Setting - Nevada Edition

Pharmacy PrEP Education: A “How-to” Series Spanning Policy to Practice

Activity
Providing PEP/PrEP in the Pharmacy Setting - Oregon Edition

Pharmacy PrEP Education: A “How-to” Series Spanning Policy to Practice

Activity
Providing PEP/PrEP in the Pharmacy Setting - Virginia Edition

Pharmacy PrEP Education: A “How-to” Series Spanning Policy to Practice

Activity
Providing PEP/PrEP in the Pharmacy Setting: A Comprehensive User Guide

Pharmacy PrEP Education: A “How-to” Series Spanning Policy to Practice

Activity
Activity for event:Assessing Pros and Cons of ART Regimens

How to Counsel Your HIV Patients as Treatment Choices Expand

Relevant Resources

Acute Management of Migraine Attacks

Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes

Clinical Updates on the Management of Gout

Evidence-Based Strategies for Improved Patient Outcomes

Opioid-Induced Constipation

Proactive Diagnosis and Targeted Management

Chronic Obstructive Pulmonary Disease, Asthma, or Both

Differential Diagnosis and Comprehensive Management Strategies

Improving Outcomes in Chronic Obstructive Pulmonary Disease

Optimizing Maintenance Therapy Across Healthcare Settings

Managing Gout in Primary Care

Evolving Strategies for Diagnosis and Long-Term Management

Clinical Issues in Chronic Pain

Consensus and Controversies for Responsible Opioid Prescribing

Noninsulin Approaches to Managing Type 2 Diabetes

Best Practices in Combination Therapy

Hitting the Target in Type 2 Diabetes

Evolving Approaches to Insulin Based Therapy

Clearing the Air

Improving Outcomes for Patients with COPD

Clinical Updates in Type 2 Diabetes

New Strategies for Insulin Replacement Therapy

How Low Do You Go?

Clinical Updates in LDL-C Management

Incretin-Based Therapies For Type 2 Diabetes

Improving Comprehensive Patient Care

Improving Outcomes in Non–24-Hour Sleep-Wake Disorder

Identifying Patients and Tailoring Therapy

Comprehensive Management of Chronic Obstructive Pulmonary Disease

Collaborative Approaches to Guideline-Concordant Patient Care

Clinical Updates in the Management of Severe Asthma

New Strategies for Individualizing Long-term Care

Comprehensive Chronic Pain Management

A Focus on Patients With Opioid-Induced Constipation

Clinical Issues in Bipolar Depression

Consensus and Controversies Across the Spectrum of Patient Presentations

Clinical Updates in Rheumatoid Arthritis

Evolving Treatment Algorithms and Expert Perspectives on Biosimilars

Caring for Patients with Severe Asthma

Evolving Best Practices to Optimize Outcomes

PrEP for Your Patients’ Needs

The PCPs Role in Preventing HIV

Can You Spot Axial Spondyloarthritis?

The PCP’s Role in Timely Recognition and Referral

Value-Based HIV Formularies

Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care

Hepatitis C is Curable

Got it? Treat it!

Real-World Issues in HIV Prevention & Treatment

The Critical Role of the Community Pharmacist

BLOCK HIV/HCV

Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.

Evolving Models of HIV Care

Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box

Advancing the Care of Severe Asthma

Differential Diagnosis, Multidisciplinary Management, and Patient Engagement

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

Clinical Issues in Chronic Liver Disease

Hot Topics in HBV, HCV, and NASH

Evolving Models of HIV Care

Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice

Assessing Your Patients for HCV and HIV

Why It Matters in OB/GYN Practice Today

Clearing the Air in Severe Asthma Management

Improving Patient Outcomes Through Shared Clinical Decision Making

HIV as a Chronic Disease

A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities

The Pursuit of Hepatitis C Elimination

How the Pharmacist Can Make a Difference

GLP-1 Receptors Agonists in Type 2 Diabetes

Mechanistic Insights and Evolving Treatment Options

Trends in Infectious Diseases: Updates on Treatment & Prevention Strategies for HIV and HCV

Understanding the Growing Syndemic — Opioids, HCV, and HIV

Airing It Out

A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis

COPD in Managed Care

The Clinical and Utilization Benefits of Exacerbation Prevention

Assimilating the Evidence in T2DM

Cardiovascular and Renal Outcomes With SGLT2 Inhibitors

Demystifying New Evidence for COPD Management

Best Practices for Primary Care

Finding Relief in Osteoarthritis

New Paths to Chronic Pain Management

Stepping Up to the Challenge

The PCP’s Role in HCV Elimination

The Changing Landscape of HIV Prevention

What the Pharmacist Needs to Know about PrEP

Evolving Models of HIV Care (Volume 3)

The Rapid ART Standard of Care: From Evidence to Healthcare Equity

What’s New in Systemic Lupus Erythematosus?

Unlocking Novel Paths to Patient Care

HIV Updates for Pharmacy Practice

Maximizing Your Role to Impact Patient Outcomes

BRIDGE HCV

Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV

Case Challenges in HIV Medicine

Benefits, Barriers, & Best Practices in an Advancing Field

Challenges and Opportunities in HIV

Practical Solutions Across the Spectrum of Care

Expanding HIV Prevention in Colorado—and Nationwide

A PEP/PrEP Training Guide for Pharmacists

Expert Views on the Changing Landscape in RA

The Increasing Role of JAK Inhibitors

COPD Cases & Conversations

Preventing COPD Exacerbations to Improve Outcomes

Treating Hepatitis C in the Primary Care Setting

A Critical Step Toward HCV Elimination

Honing Clinical Skills in HIV Treatment

Considering the Patient, the Provider, and the Science

Hot Topics in HCV

A Multidisciplinary Online Mini-Curriculum

Comprehensive Management in COPD

A Whole Patient Case Series

Clinical Issues in COVID-19

Debates and Discussions about Monoclonal Antibody Therapies

Minimizing Patient Risks From COVID-19

An Update on Monoclonal Antibody Therapies

Maybe It’s NOT Mechanical Back Pain

Getting on the Fast Track to Identify AxSpA

Treating Hepatitis C in the Primary Care Setting

Establishing Clinical Readiness Through Mentored Learning

Finding the Path in Eosinophilic Esophagitis

Interdisciplinary Strategies for Adult and Pediatric Patients

Answering the Call

Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema

Getting Low in Familial Hypercholesterolemia

Reducing LDL-C and a Lifetime of Cardiovascular Risk

Expert Consult Series in Multiple Sclerosis

Updates, Clinical Scenarios, and Future Directions

Putting a Spotlight on Systemic Mastocytosis

A Multidisciplinary Look at Early Diagnosis and Management

Clinical Updates in COVID-19

Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment

Is It Systemic Mastocytosis?

Best Practices for Diagnosis and Management

Monoclonal Antibodies for COVID-19

An Update on Best Practices

Monoclonal Antibodies for COVID-19

New Avenues to Pre-Exposure Prophylaxis

Early Cancer Detection in Primary Care:

Are You Aware of New Blood-Based Multi-Cancer Screening Tools

Virologic Failure in HIV

An Updated Clinician’s Guide to Assessment and Management

Applying HIV Advances in Practice

What the Pharmacist Needs to Know

Buffing Up on New and Emerging ART

A Look at the Changing HIV Playing Field

BRIDGE PrEP

Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention